References
- 1Louis ED, McCreary M. How Common is Essential Tremor? Update on the Worldwide Prevalence of Essential Tremor. Tremor and Other Hyperkinetic Movements. 2021; 11(1): 28. DOI: 10.5334/tohm.632
- 2Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord. 2010; 25(5): 534–41. DOI: 10.1002/mds.22838
- 3Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018; 33(1): 75–87. DOI: 10.1002/mds.27121
- 4Ferreira JJ, Mestre TA, Lyons KE, Benito-Leon J, Tan EK, Abbruzzese G, et al. MDS evidence-based review of treatments for essential tremor. Mov Disord. 2019; 34(7): 950–8. DOI: 10.1002/mds.27700
- 5Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB,
Jr. , et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005; 64(12): 2008–20. DOI: 10.1212/01.WNL.0000163769.28552.CD - 6Louis ED, Rohl B, Rice C. Defining the Treatment Gap: What Essential Tremor Patients Want That They Are Not Getting. Tremor Other Hyperkinet Mov (N Y). 2015; 5: 331. DOI: 10.5334/tohm.239
- 7Koller WC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: report on 678 patients. Essential Tremor Study Group. Ann Neurol. 1994; 35(6): 717–23. DOI: 10.1002/ana.410350613
- 8Diaz NL, Louis ED. Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists. Parkinsonism Relat Disord. 2010; 16(9): 604–7. DOI: 10.1016/j.parkreldis.2010.07.011
- 9Hedera P, Cibulcik F, Davis TL. Pharmacotherapy of essential tremor. J Cent Nerv Syst Dis. 2013; 5: 43–55. DOI: 10.4137/JCNSD.S6561
- 10Louis ED, Rios E, Henchcliffe C. How are we doing with the treatment of essential tremor (ET)?: Persistence of patients with ET on medication: data from 528 patients in three settings. Eur J Neurol. 2010; 17(6): 882–4. DOI: 10.1111/j.1468-1331.2009.02926.x
- 11Serrano-Duenas M. Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord. 2003; 10(1): 29–33. DOI: 10.1016/S1353-8020(03)00070-1
- 12O’Suilleabhain P, Dewey RB,
Jr . Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord. 2002; 17(2): 382–6. DOI: 10.1002/mds.10083 - 13Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006; 66(5): 672–7. DOI: 10.1212/01.wnl.0000200779.03748.0f
- 14Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000; 15(4): 678–82. DOI: 10.1002/1531-8257(200007)15:4<;678::AID-MDS1012>3.0.CO;2-0
- 15Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology. 1987; 37(3): 471–4. DOI: 10.1212/WNL.37.3.471
- 16Calzetti S, Findley LJ, Gresty MA, Perucca E, Richens A. Metoprolol and propranolol in essential tremor: a double-blind, controlled study. J Neurol Neurosurg Psychiatry. 1981; 44(9): 814–9. DOI: 10.1136/jnnp.44.9.814
- 17Koller WC, Biary N. Metoprolol compared with propranolol in the treatment of essential tremor. Arch Neurol. 1984; 41(2): 171–2. DOI: 10.1001/archneur.1984.04050140069026
- 18Larsen TA, Teravainen H, Calne DB. Atenolol vs. propranolol in essential tremor. A controlled, quantitative study. Acta Neurol Scand. 1982; 66(5): 547–54. DOI: 10.1111/j.1600-0404.1982.tb03141.x
- 19Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996; 11(3): 250–6. DOI: 10.1002/mds.870110306
- 20Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001; 56(11): 1523–8. DOI: 10.1212/WNL.56.11.1523
- 21Samotus O, Kumar N, Rizek P, Jog M. Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics. Can J Neurol Sci. 2018; 45(1): 11–22. DOI: 10.1017/cjn.2017.260
- 22Niemann N, Jankovic J. Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018; 10(7). DOI: 10.3390/toxins10070299
- 23Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology. 1986; 36(7): 1001–4. DOI: 10.1212/WNL.36.7.1001